Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 191
---
 that the beneficial owners
of the Ordinary Shares listed below have sole investment and voting power with respect to such shares.

Following the closing of this
offering, all of our shareholders, including the shareholders listed below, will have the same voting rights attached to their Ordinary
Shares, and neither our principal shareholders nor our directors and executive officers will have different or special voting rights with
respect to their Ordinary Shares. See “Description of Share Capital—Voting Rights.” A description of any material relationship
that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is included under
“Certain Relationships and Related Party Transactions.”

Unless otherwise noted below,
the address of each shareholder, director and executive officer is c/o Regentis Biomaterials Ltd., 60 Medinat Hayehudim Street, Herzliya
4676652, Israel.

|                                                             |     | Ordinary     
 Shares       |           |     | Percentage of      
 Ordinary Shares    
 beneficially owned |      |   |     |          |      |   |
| Name of beneficial owner                                    |     | beneficially 
 owned        |           |     | Before             
 offering           |      |   |     | After    
 offering |      |   |
| 5% or Greater Shareholders                                  |     |              |           |     |                    |      |   |     |          |      |   |
| HaisThera Scientific Fund I, L.P.(1)                        |     |              |   616,607 |     |                    | 15.7 | % |     |          | 12.5 | % |
| Ocorian Fund Management S.à r.l (2)                         |     |              |   296,372 |     |                    |  7.5 | % |     |          |  6.0 | % |
| SCP Vitalife Partners II, L.P. (3)                          |     |              |   270,472 |     |                    |  6.9 | % |     |          |  5.5 | % |
| Medica III Investments (International) LP (4)               |     |              |   261,780 |     |                    |  6.7 | % |     |          |  5.3 | % |
| DSM Venturing B.V.(5)                                       |     |              |   261,020 |     |                    |  6.6 | %